SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Teva Pharmaceuticals
TEVA 32.65+0.5%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ariella who wrote (174)3/27/1998 8:54:00 AM
From: Harold Engstrom  Read Replies (1) of 340
 
I am a Biogen investor, but try to look at things objectively. Still, the "evidence" that copaxone slows progression of MS was not conducted under the rigorous conditions of a clinical study, but was funded research at universities. Who funded the research? Hopefully, the findings are accurate for the sake of patients. But, when applying for approval in the US under the strict criteria that clinical studies impose, Teva was unable to show slower progression of the disease with Copaxone.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News